Chugai expects no impact on top seller Avastin following US breast cancer decision
This article was originally published in Scrip
Executive Summary
Roche's Japanese subsidiary Chugai does not expect its continued sale of Avastin (bevacizumab) in Japan to be affected by the recent US FDA revocation of approval for the product in metastatic breast cancer.